{"id":158,"date":"2024-02-21T12:14:02","date_gmt":"2024-02-21T10:14:02","guid":{"rendered":"https:\/\/webs.uab.cat\/therCNS\/?page_id=158"},"modified":"2026-07-08T12:01:37","modified_gmt":"2026-07-08T10:01:37","slug":"technology-transfer-patents-and-spin-offs-m","status":"publish","type":"page","link":"https:\/\/webs.uab.cat\/therCNS\/technology-transfer-patents-and-spin-offs-m\/","title":{"rendered":"Technology Transfer (Patents and Spin-offs)"},"content":{"rendered":"\n

Spin-offs<\/mark><\/h2>\n\n\n\n
\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

Nanotherapix SL<\/strong>.Technology-based company dedicated to the research and development of gene therapy treatments for autoimmune and inflammatory diseases based on the use of an adenoviral vector platform to target monocytes and macrophages specifically and efficiently. Funded in Barcelona in 2009 by Dr. M.A. Gassull (IGTP), Dra. E. Fernandez (UAB); Dr. A. Rio (IGTP), and Dr. M. Chill\u00f3n (ICREA, UAB).<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

Kogenix Therapeutics<\/strong>. Technology-based company dedicated to the research and development of gene therapy strategies to reduce and delay the progression of cognitives impairments and neurodegenerative diseases associated with aging using the secreted form of the klotho chronokine as a therapeutic drug. Funded in Boston (USA) in 2016 by Dra. C. Abraham (Univ Boston), Dr. M. Abraham; Dra. A. Bosch (UAB), and Dr. M. Chill\u00f3n (ICREA, UAB).<\/p>\n<\/div>\n<\/div>\n\n\n\n

Patents<\/mark><\/h2>\n\n\n\n
    \n
  • New constructs for gene therapy of MLC1 and other astrocytopathies. Inventors: A Bosch, A Brao, M Chillon, I.Rodriguez. Appplication number: EP26382671.1. Priority date: 11\/5\/2026.<\/li>\n\n\n\n
  • Klotho fusion protein and uses thereof. Inventors: M Chillon, J Esandi, B Almolda, A Bosch, X Daura, O Conchillo, J Giraldo, PV Renault de Barrios. Appplication number: EP23382593.4. Priority date: 15\/6\/2023.<\/li>\n\n\n\n
  • Secreted splicing variant of klotho for extending lifespan. Inventors: M Chillon, A Bosch, J Roig. Appplication number: EP22383171.0. Priority date: 2\/12\/2022. <\/li>\n\n\n\n
  • Secreted splicing variant of klotho for treating muscle disorders. Inventors: M Chillon, A Bosch, J Roig, P Mu\u00f1oz. Application number: EP22383173.6. Priority date: 2\/12\/2022.  <\/li>\n\n\n\n
  • Nucleic acid constructs and vectors for podocyte specific expression. A. Meseguer, M. Chill\u00f3n, J. Ar\u00e9valo. Appplication number: US 18\/862,451. Priority date: 11\/01\/2024. Licensing company: Ninevah Therapeutics<\/li>\n\n\n\n
  • Treatment of neuromuscular diseases via gene therapy that expresses klotho protein. Inventors: A Bosch, S Verd\u00e9s, M Herrando, X Navarro, M Chillon. Application number: US63\/330.684. Priority date: 13\/04\/22. Licensing companies: ANEW (USA). <\/li>\n\n\n\n
  • Secreted Splicing variant of klotho for treating bone disorders. Inventors: J Roig, M Chillon, A Bosch, M Pall\u00e0s, C Gri\u00f1an. Application number: WO2022\/243519-A1. Priority date: 21\/5\/21.  <\/li>\n\n\n\n
  • Vectors expressing klotho for treating cancer. Inventors: C Abraham, M Abraham, A Bosch, M Chillon T Rubinek, I Wolf. Application number: PCT\/IL2019\/050913. Priority Date: 28\/8\/19. Licencing company: Klogene<\/li>\n\n\n\n
  • Secreted splicing variant of mammal Klotho as a medicament for cognition and behaviour impairments. Inventors: M.Chill\u00f3n, A.Mass\u00f3, A. Bosch. Application number: EP15195470.8. Priority Date: 19\/11\/15. Licencing company: ANEW (USA) <\/li>\n\n\n\n
  • Antibodies against mammal secreted Klotho protein. Inventors: M.Chill\u00f3n, A.Mass\u00f3, A. Bosch. Application number: EP15160093.9. Priority Date: 20\/03\/15. <\/li>\n\n\n\n
  • M\u00e9todo para la producci\u00f3n de adenovirus mosaico. Inventors: M. Chillon, M. Miralles, E. Rodriguez, A. Bosch. Application number: PCT\/ES2011\/070897. Priority Date: 24\/12\/10. <\/li>\n\n\n\n
  • Methods and reagents for efficient and targeted gene transfer to monocytes and macrophages. Inventors: M.A. Gassull, A. Rio, E. Fern\u00e1ndez, M. Chillon. Application number: WO2010125115 ; EP09159001.8; 20100101463. Priority Date: 28\/04\/10. Licencing company: Nanotherapix<\/li>\n\n\n\n
  • Transpos\u00f3n Hsmar2 y su uso en la generaci\u00f3n de vectores \u00fatiles en terapia g\u00e9nica som\u00e1tica. Inventors: M. Chillon, O. Danos, E. Gil, A. Bosch, R. Alba. Application number: P200602688. Priority Date: 18\/10\/06. <\/li>\n\n\n\n
  • M\u00e9todo de producci\u00f3n de vectores adenovirus para terapia g\u00e9nica y secuencias de ADN \u00fatiles para ello. Inventors: M. Chillon, R. Alba, A. Bosch. Application number: WO 2007\/125146. Priority Date: 28\/04\/06.<\/li>\n\n\n\n
  • Canine adenovirus vectors for the transfer of genes in targeted cells. Inventors: Eric Kremer, Miguel Chillon, Claire Soudais, Sylvie Boutin, Elise Peltekian, Luis Garcia, Nathalie Vincent, Olivier Danos. Application number: WO 01\/42481 A2. Priority Date: 7\/12\/1999. <\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"

    Spin-offs Nanotherapix SL.Technology-based company dedicated to the research and development of gene therapy treatments for autoimmune and inflammatory diseases based on the use of an adenoviral vector platform to target monocytes and macrophages specifically and efficiently. Funded in Barcelona in 2009 by Dr. M.A. Gassull (IGTP), Dra. E. Fernandez (UAB); Dr. A. Rio (IGTP), and […]<\/p>\n","protected":false},"author":2848,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-158","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/webs.uab.cat\/therCNS\/wp-json\/wp\/v2\/pages\/158","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/webs.uab.cat\/therCNS\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/webs.uab.cat\/therCNS\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/webs.uab.cat\/therCNS\/wp-json\/wp\/v2\/users\/2848"}],"replies":[{"embeddable":true,"href":"https:\/\/webs.uab.cat\/therCNS\/wp-json\/wp\/v2\/comments?post=158"}],"version-history":[{"count":18,"href":"https:\/\/webs.uab.cat\/therCNS\/wp-json\/wp\/v2\/pages\/158\/revisions"}],"predecessor-version":[{"id":1390,"href":"https:\/\/webs.uab.cat\/therCNS\/wp-json\/wp\/v2\/pages\/158\/revisions\/1390"}],"wp:attachment":[{"href":"https:\/\/webs.uab.cat\/therCNS\/wp-json\/wp\/v2\/media?parent=158"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}